Science and Technology Innovation Board pharmaceutical companies concentrate on disclosing research and development progress. YAHONG Pharmaceuticals' globally innovative product obtains approval.

On the evening of March 3, Yuhong Pharmaceuticals, Bio-Thera, Haichuang Pharmaceuticals and other six biopharmaceutical companies on the Science and Technology Innovation Board collectively disclosed progress in drug registration and research and development. Yuhong Pharmaceuticals announced that they have received the Drug Registration Certificate issued by the National Medical Products Administration, approving the listing of APL-1702 for the treatment of patients aged 18 and above confirmed by histology as having CIN2, becoming the world's first non-surgical non-invasive treatment product approved for this patient population. Bio-Thera announced that their Usymro has received approval for listing from the UK MHRA, indicated for moderate to severe plaque psoriasis, active psoriatic arthritis and other indications. As of now, this product has been approved for listing by the US FDA, European EMA, and UK MHRA, with commercialization partnerships covering 71 countries and regions worldwide. The intensive research and development progress highlights the strong innovative capabilities of biopharmaceutical companies on the Science and Technology Innovation Board.